Key Takeaways
- • Hologic, backed by Blackstone and TPG, has agreed to a deal to acquire Barcelona-based precision oncology firm Reveal Genomics.
- • Reveal Genomics develops genomic diagnostic tests designed to guide cancer treatment decisions, including HER2DX for HER2-positive breast cancer.
- • The primary source provides limited detail on deal terms, valuation, and closing timeline, so these remain unreported in the available material.
Summary
Hologic, the medical technology company backed by private equity firms Blackstone and TPG, has agreed to a deal involving Reveal Genomics, a precision oncology company based in Barcelona, according to the original report. Reveal Genomics develops genomic diagnostic tests intended to guide cancer treatment, with its HER2DX test for HER2-positive breast cancer cited as a representative product.
The transaction highlights continued private equity interest in precision oncology and molecular diagnostics, a segment where genomic testing is increasingly used to inform therapy selection. The available source material does not disclose the purchase price, deal structure, or expected completion date, and it does not provide further detail on Reveal Genomics' revenues or commercial footprint. Readers seeking valuation and transaction terms should consult the full article or subsequent filings.
The transaction highlights continued private equity interest in precision oncology and molecular diagnostics, a segment where genomic testing is increasingly used to inform therapy selection. The available source material does not disclose the purchase price, deal structure, or expected completion date, and it does not provide further detail on Reveal Genomics' revenues or commercial footprint. Readers seeking valuation and transaction terms should consult the full article or subsequent filings.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.